Lupitidine

Lupitidine (INN; lupitidine hydrochloride (USAN); development code SKF-93479) is a long-acting H2 receptor antagonist[1] developed by Smith, Kline & French and described as an antiulcerogenic that was never marketed.[2] It was shown to inhibit nocturnal gastric acid secretion[3] and, in experiments on rodents, produced diffuse neuroendocrine cell hyperplasia and an increase in multifocal glandular hyperplasia due to hypergastrinemia resulting from the pharmacological suppression of gastric acid secretion.[4]

Lupitidine
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC21H27N5O2S
Molar mass413.54 g/mol g·mol−1
3D model (JSmol)


References

  1. Franzén, L; Ghassemifar, R; Malcherek, P (July 1991). "Experimental Mast Cell Activation Improves Connective Tissue Repair in the Perforated Rat Mesentery". Agents and Actions. 33 (3–4): 371–7. doi:10.1007/bf01986588. PMID 1683107.
  2. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 745–. ISBN 978-1-4757-2085-3.
  3. Dammann, H.G.; Muller, P.; Simon, B. (January 1982). "Inhibition of Nocturnal Acid Secretion by H2-Receptor-Antagonist SKF 93479". The Lancet. 319 (8265): 224. doi:10.1016/S0140-6736(82)90788-7.
  4. Betton, GR; Dormer, CS; Wells, T; Pert, P; Price, CA; Buckley, P (1 February 1988). "Gastric ECL-Cell Hyperplasia and Carcinoids in Rodents Following Chronic Administration of H2-antagonists SK&F 93479 and Oxmetidine and Omeprazole". Toxicologic Pathology. 16 (2): 288–298. doi:10.1177/019262338801600222. PMID 2903544.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.